AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35193054
Drug: SCT630 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCT630 (40 mg)
Trial: 33619820
Drug: Cream applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream applied with expectation of pain reduction after 5 minutes (P5)
Trial: 33619820
Drug: Cream applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream applied with expectation of pain reduction after 30 minutes (P30)
Trial: 33619820
Drug: Cream with
RxNorm normalized name: CREAM WITH APPLICATOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream with no analgesic expectation (NE)
Trial: 36479231
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) alone
Trial: 35811600
Drug: Peer-led preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer-led preventive oral health education
Trial: 35811600
Drug: Class-based lecture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class-based lecture on oral health (Control)
Trial: 39671076
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg twice daily
Trial: 34665856
Drug: Salbutamol (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (24 mg oral)
Trial: 35319669
Drug: Antibiotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic group (GAtb) - 500 mg amoxicillin + 400 mg metronidazole
Trial: 36459138
Drug: High-dose erythropoietin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose erythropoietin
Trial: 32981043
Drug: GONB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GONB with bupivacaine 0.5% (3 mL each side)
Trial: 39606837
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available therapy
Trial: 34848180
Drug: Intramuscular depot
RxNorm normalized name: Primoteston Depot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular depot medroxyprogesterone acetate (DMPA‐IM)
Trial: 33942167
Drug: NIPEC (Normothermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NIPEC (Normothermic Intraperitoneal Chemotherapy)
Trial: 33942167
Drug: Standardized cytoreductive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized cytoreductive surgery and perioperative chemotherapy
Trial: 36348313
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy counseling (8 systematic desensitization sessions, 2-3 sessions per week)
Trial: 36348313
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy counseling
Trial: 33865577
Drug: Ad libitum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad libitum rate of MR (ADLIB; offered twice daily for 35 d, 0.66 kg/d for 4 d, and 0.33 kg/d for 3 d)
Trial: 33108521
Drug: Cod (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod (750 g/week)
Trial: 32591326
Drug: Pharmaceutical training
RxNorm normalized name: PHARMACEUTICAL GLAZE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical training program without a communication component
Trial: 35552673
Drug: Palbociclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib (125 mg orally/day; 3/1 week schedule) and Fulvestrant (500 mg intramuscularly)
Trial: 35552673
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and Fulvestrant (500 mg intramuscularly)
Trial: 32248591
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin D supplementation (400 IU/d)
Trial: 33189562
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of CDK4/6 inhibitors (CDK4/6i) beyond first disease progression (PD)
Trial: 32783667
Drug: CDK4/6 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitors (CDK4/6i)
Trial: 36881395
Drug: Beta-blocker
RxNorm normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker
Trial: 32037380
Drug: Diuretic
RxNorm normalized name: Diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic
Trial: 36293365
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Betula alba and Empetrum nigrum extracts
Trial: 38385941
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 mg
Trial: 36394498
Drug: Acceptance-Based Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-Based Therapy (ABT) intervention, 15 virtual, 90-minute group sessions.
Trial: 36394498
Drug: Enhanced care,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced care, 15 healthy lifestyle handouts, met virtually twice with a registered dietitian.
Trial: 33689702
Drug: CDK4/6 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDK4/6 inhibitors (specific inhibitors not mentioned)
Trial: 36065041
Drug: 6-week reactive
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week reactive agility training program using light-based stimuli (Witty SEM light stimulus), 60-min training sessions twice a week
Trial: 35303509
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) delivered by the CyberKnife® system targeting resection margin one month after surgery; total dose of 35 Gy.
Trial: 35303509
Drug: Surgery alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery alone (SA) group; no specific dosage mentioned.
Trial: 33047417
Drug: Copayment elimination
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Copayment elimination for cardioprotective medications
Trial: 34774196
Drug: BBV152 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBV152 vaccine (two intramuscular doses administered 4 weeks apart)
Trial: 34774196
Drug: BBV152 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBV152 vaccine
Trial: 35511655
Drug: Lenoid™ topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenoid™ topical treatment
Trial: 34262151
Drug: Strength or
RxNorm normalized name: Regular Strength Orajel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength or balance exercise during chemotherapy treatment
Trial: 39283627
Drug: Erenumab 140
RxNorm normalized name: Erenumab 140 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab 140 mg
Trial: 37699636
Drug: Intravenous hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydration
Trial: 36189008
Drug: Treatment-as-usual control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual control
Trial: 35078841
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Conventional intravenous induction without topical anaesthesia)
Trial: 32519032
Drug: Liquid 6MP
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid 6MP formulation (20 mg/ml)
Trial: 32519032
Drug: 6MP tablet
RxNorm normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6MP tablet (50 mg)
Trial: 32835607
Drug: EM-β-carotene (emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EM-β-carotene (emulsion dispersion formulation)
Trial: 32835607
Drug: CR-β-carotene (crystal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR-β-carotene (crystal dispersion formulation)
Trial: 34029707
Drug: Extended infusion
RxNorm normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended infusion (EI)
Trial: 34564759
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 µg/kg
Trial: 36260325
Drug: hsTnT increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsTnT increase of 7 ng/L or more
Trial: 36260325
Drug: Stable hsTnT
RxNorm normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stable hsTnT values (change <3 ng/L)
Trial: 39636024
Drug: Oral moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral moxifloxacin
Trial: 32459420
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of oral dronabinol
Trial: 34119499
Drug: Prophylaxis +
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis + cefazolin 2 g IV × 3 followed by oral amoxicillin/clavulanate 3 g/day (Group B)
Trial: 34119499
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (Prophylactic cefazolin 2 g IV)
Trial: 34119499
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (Prophylaxis + cefazolin 2 g IV × 3 followed by oral amoxicillin/clavulanate 3 g/day)
Trial: 35490404
Drug: BAY 1831865
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1831865 (3.5, 7, 17, 35, 75, or 150 mg i.v. or 150 mg s.c.)
Trial: 36096984
Drug: Sorafenib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg orally twice daily continuously
Trial: 33905902
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of 2% lidocaine and 0.5% bupivacaine (20 mL mixture: 10 mL each)
Trial: 33905902
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of 2% lidocaine (10 mL) followed by 0.5% bupivacaine (10 mL) after 120 s
Trial: 33905902
Drug: Combined administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined administration of 2% lidocaine and 0.5% bupivacaine
Trial: 34813038
Drug: Total radiation
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total radiation dose in closure group
Trial: 34813038
Drug: Total radiation
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total radiation dose in nonclosure group
Trial: 33811400
Drug: 1% phytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% phytic acid solution and EndoSequence BC sealer
Trial: 33811400
Drug: 17% EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17% EDTA solution and EndoSequence BC sealer
Trial: 32251400
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy (3 patients in safety run-in)
Trial: 34060166
Drug: Cutaneous stimulation
RxNorm normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cutaneous stimulation therapy
Trial: 32118696
Drug: Chronic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chronic low-dose carbon monoxide (CO) administration
Trial: 34399066
Drug: Spirulina supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina supplementation (6 g/day for 21 days)
Trial: 37055702
Drug: i-gel
RxNorm normalized name: Di-Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel
Trial: 36000374
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A eye gel combined with 3M transparent tape
Trial: 36000374
Drug: Erythromycin eye
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin eye ointment combined with 3M transparent tape
Trial: 32913021
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg escitalopram × 2 weeks
Trial: 32913021
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg escitalopram × 8 weeks
Trial: 32913021
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg escitalopram × 8 weeks
Trial: 36301305
Drug: Parent-Adolescent (PA)
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-Adolescent (PA) treatment condition
Trial: 32089456
Drug: LDL-C goal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL-C goal <50 mg/dL for all patients in secondary prevention or very high-risk primary prevention; optional goal ≤30 mg/dL for category A extreme-risk patients; recommended goal ≤30 mg/dL for category B extreme-risk patients.
Trial: 39315857
Drug: FACT-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FACT-G
Trial: 32382685
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no drug)
Trial: 34133856
Drug: Tofacitinib (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (10 mg twice daily for up to 14 days)
Trial: 34133856
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for up to 14 days)
Trial: 36008352
Drug: Fluid volume
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid volume quartile 4 (1258-2790 ml)
Trial: 36008352
Drug: Fluid administration
RxNorm normalized name: Fluid Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid administration of 1000 ml starting at least 1 hour before contrast injection and continuing for 6 hours
Trial: 36008352
Drug: Mean fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean fluid volumes <964 ml
Trial: 34320864
Drug: Fluorouracil 1%
RxNorm normalized name: FLUOROURACIL 1% CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil 1% cream
Trial: 34157578
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg methotrexate (MTX) per week
Trial: 32470924
Drug: NZBC extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NZBC extract (CurraNZ™) 300 mg/day
Trial: 36329165
Drug: Fluorescein Angiography
RxNorm normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluorescein Angiography (FA) guided laser treatment
Trial: 34953042
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction chemotherapy
Trial: 33514869
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (100 ml of Lactobacillus casei strain Shirota)
Trial: 32324471
Drug: Block-structured training
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Block-structured training alternating weekly between blood flow restricted low-load resistance training (BFR-RT) at 20% 1-RM and heavy-load resistance training (HL-RT) at 70-90% 1-RM (BFR-HRT, n = 9)
Trial: 35926074
Drug: Curated social
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curated social web app for COVID-19 vaccine information
Trial: 33077275
Drug: High fibre
RxNorm normalized name: Adult high protein high fibre formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fibre flatbread with enzymatically released free FA (14.22 mg)
Trial: 33077275
Drug: Standard high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard high fibre bread (2.34 mg)
Trial: 33077275
Drug: White bread
RxNorm normalized name: White bread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White bread control (0.48 mg)
Trial: 39438214
Drug: Lidocaine infusion
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine infusion
Trial: 36204877
Drug: Ethanol injection
RxNorm normalized name: ethanol Injection
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol injection combined with 125I radioactive seed implantation
Trial: 36204877
Drug: Ethanol injection
RxNorm normalized name: ethanol Injection
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol injection alone
Trial: 32183895
Drug: Placebo (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dosage not specified)
Trial: 36123843
Drug: Dexamethasone injection
RxNorm normalized name: dexamethasone Injection
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone injection preoperatively
Trial: 36123843
Drug: Dexamethasone injection
RxNorm normalized name: dexamethasone Injection
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone injection preoperatively and topical honey application
Trial: 34032731
Drug: Puerarin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puerarin (150 mg/d for 3 months)
Trial: 35089372
Drug: lidocaine 0.5
RxNorm normalized name: LIDOCAINE 0.5% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 0.5 mg/kg (Group III)
Trial: 35089372
Drug: lidocaine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 1.0 mg/kg (Group IV)
Trial: 33049411
Drug: Oral TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral TXA (1 g at 4, 10, and 16 hours postoperatively)
Trial: 33049411
Drug: Intravenous TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TXA (0.5 g at 6, 12, and 18 hours postoperatively)
Trial: 36437383
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin plus 10 mg ezetimibe
Trial: 36437383
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rosuvastatin alone
Trial: 36437383
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ezetimibe alone
Trial: 36437383
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ezetimibe plus 10 mg rosuvastatin
Trial: 34101900
Drug: Calcifediol 0.266
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcifediol 0.266 mg/month for 12 months
Trial: 34101900
Drug: Calcifediol 0.266
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcifediol 0.266 mg/month for 4 months followed by placebo for 8 months
Trial: 32912942
Drug: Probiotic Peanut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Peanut Oral ImmunoTherapy (PPOIT)
Trial: 38047365
Drug: Treatment-as-Usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-Usual (TAU)
Trial: 33203026
Drug: Extreme learning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extreme learning based solutions
Trial: 33549732
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy intervention
Trial: 32184653
Drug: IV morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV morphine
Trial: 32367867
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg (Group T)
Trial: 32367867
Drug: Saline 4
RxNorm normalized name: DRESSING,WET SALINE 4IN X 8IN KEN#3606
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 4 ml (Group S)
Trial: 38787930
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis (IVT)
Trial: 32769878
Drug: AZL‐M 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL‐M 80 mg
Trial: 32769878
Drug: AZL‐M 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL‐M 40 mg
Trial: 32769878
Drug: valsartan 160 mg
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: valsartan 160 mg
Trial: 33722866
Drug: Free distribution
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free distribution of medicines
Trial: 37461207
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A
Trial: 37461207
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B
Trial: 36239788
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (Control)
Trial: 37158751
Drug: no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment (control)
Trial: 34930617
Drug: veliparib during
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: veliparib during chemotherapy and maintenance (veliparib-throughout)
Trial: 36341232
Drug: Standard-care (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-care (low FODMAP diet, Otilonium Bromide 1 tablet TID, multi-strain probiotic 1 capsule BID for 1 month)